Tetraphase falls on Phase III cUTI miss

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) lost $3.28 (60%) to $2.15 on Wednesday after reporting that IV eravacycline (TP-434) missed the co-primary endpoints in the Phase III IGNITE3 trial to treat complicated urinary tract infections (cUTIs). The company announced the news after market close on Tuesday.

On the 1,205-patient trial's co-primary endpoints, eravacycline failed to achieve non-inferiority to ertapenem in responder rate as measured by a combination of clinical cure and microbiological success in the microbiological intent-to-treat (MITT) population at both the end-of-IV treatment visit (84.8% vs. 94.8%) and the test-of-cure (TOC) visit 5-10 days after the end of therapy (68.5% vs. 74.9%). Tetraphase said it is currently analyzing the data and will provide an update on next steps for eravacycline to treat cUTIs at a later date...